{
    "id": 18235,
    "cites": 25,
    "cited_by": 1,
    "reference": [
        "World Health Organization (2012), Life Tables for 2009, 2000 and 1990: Summary of data and methods used, May, http://www.who.int/healthinfo/statistics/LT_method.pdf",
        "Solow RM (1960), \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Investment and technological progress,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d in K. Arrow, S. Karlin and P.",
        "Suppes (eds.), Mathematical Methods in Social Sciences 1959 (Stanford: Stanford University Press), 89-104.",
        "Sampat BN, Lichtenberg FR (2011), \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093What are the Respective Roles of the Public and Private Sectors in Pharmaceutical Innovation?,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Health Affairs 30(2):332-9, Feb.",
        "Romer P (1990), \"Endogenous Technological Change,\" Journal of Political Economy 98 (5, Part 2), October S71-S102.",
        "Ruhm CJ (2005) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Healthy Living in Hard Times.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Health Economics 24: 341-363.",
        "National Science Foundation (2012), U.S. Corporate R&D: Volume 1: Top 500 Firms in R&D by Industry Category, http://www.nsf.gov/statistics/nsf00301/expendit.htm Nordhaus WD (2003), \"The Health of Nations: The Contribution of Improved Health to Living Standards,\" in Measuring the Gains from Medical Research: An Economic Approach, ed. K. M. Murphy and R. H. Topel (Chicago: University of Chicago Press), 9-40.",
        "Lleras-Muney A (2005), \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The relationship between education and adult mortality in the United States,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Review of Economic Studies 72 (1), 189-221.",
        "Lichtenberg FR (2013a), The impact of therapeutic procedure innovation on hospital patient longevity: evidence from Western Australia, 2000-2007. Social Science and Medicine 77: 50-9, January.",
        "Lichtenberg FR (2013b), \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Effect of Pharmaceutical Innovation on Longevity: Patient Level Evidence from the 1996\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c2002 Medical Expenditure Panel Survey and Linked Mortality Publicuse Files,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Forum for Health Economics and Policy 16(1): 1\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c33.",
        "Lichtenberg FR (2013c), \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The impact of pharmaceutical innovation on longevity and medical expenditure in France, 2000\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c2009, Economics & Human Biology, Available online 12 April., http://www.sciencedirect.com/science/article/pii/S1570677X13000373 Lichtenberg FR, Duflos G (2008), \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Pharmaceutical innovation and the longevity of Australians: a first look,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d with Gautier Duflos, Advances in Health Economics and Health Services Research 19: 95-117.",
        "Lichtenberg FR, Grootendorst P, Van Audenrode M, Latremouille-Viau D, Lefebvre P (2009). The impact of drug vintage on patient survival: a patient-level analysis using Quebec\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2s provincial health plan data. Value in Health 12 (6), 847\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c856.",
        "Lichtenberg FR (2012), \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The contribution of pharmaceutical innovation to longevity growth in Germany and France, 2001-2007,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d PharmacoEconomics 30(3): 197-211, March.",
        "Lichtenberg FR (2011), \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The quality of medical care, behavioral risk factors, and longevity growth,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d International Journal of Health Care Finance and Economics 11(1), March, 1-34.",
        "Lichtenberg FR (2005b), \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Impact of New Drug Launches on Longevity: Evidence from Longitudinal, Disease-Level Data from 52 Countries, 1982\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c2001\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d International Journal of Health Care Finance and Economics 5: 47\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c73.",
        "Leon DA (2008), \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Cities, urbanization and health,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d International Journal of Epidemiology 37:4\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c 8 http://ije.oxfordjournals.org/content/37/1/4.full.pdf+html Lichtenberg FR (2005a), \"Pharmaceutical innovation and the burden of disease in developing countries,\" Journal of Medicine and Philosophy 30(6), December.",
        "Hercowitz Z (1998), \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The 'embodiment' controversy: A review essay,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Monetary Economics 41, 217-224.",
        "Hulten, CR (1992), \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Growth accounting when technical change is embodied in capital,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d The American Economic Review 82 (4), September, 964-980.",
        "Food and Drug Administration (2013) Drug and Biologic Approval Reports > NDA Approvals by Therapeutic Potential and Chemical Type http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ DrugandBiologicApprovalReports/ucm121102.htm Ford ES, et al (2007). Explaining the Decrease in U.S. Deaths from Coronary Disease, 1980\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c 2000. N Engl J Med 356: 2388-98.",
        "Deaton A, Paxson C. (2004), \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Mortality, Income, and Income Inequality over Time in Britain and the United States,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d in Perspectives on the Economics of Aging, David A. Wise, editor (University of Chicago Press), pp. 247-280, http://www.nber.org/chapters/c10345.pdf Dorsey ER, et al (2010). Financial Anatomy of Biomedical Research, 2003\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c2008. Journal of the American Medical Association 303(2): 137\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c143.",
        "Danzon P, Wang YR, Wang L (2005). \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The impact of price regulation on the launch delay of new drugs\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009devidence from twenty-five major markets in the 1990s,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Health Economics 14 (3), 269\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c292, March.",
        "Cerda RA (2007). Endogenous innovations in the pharmaceutical industry J Evol Econ 17:473\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c Civan A, Maloney MT (2006), The Determinants of Pharmaceutical Research and Development Investments, Contributions to Economic Analysis & Policy 5(1), Article 28, http://www.fatih.edu.tr/~kcivan/research/drug-r-d-final.pdf Cutler D, Deaton A, Lleras-Muney A (2006). \"The Determinants Of Mortality,\" Journal of Economic Perspectives 20(3,Summer), 97-120.",
        "Center for Medicare and Medicaid Services (2013), National Health Expenditure Data, http://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-andReports /NationalHealthExpendData/Downloads/tables.pdf.",
        "Almond D, Mazumder B (2006), \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093How did schooling laws improve long-term health and lower mortality?,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Federal Reserve Bank of Chicago Working Paper No WP-06-23, http://www.chicagofed.org/publications/workingpapers/wp2006_23.pdf Bahk B, Gort M (1993), \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Decomposing Learning by Doing in New Plants,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Political Economy 101, 561-583.",
        "Acemoglu D, Linn J (2004). \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Quarterly Journal of Economics 119(3): 1049\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1090, August."
    ]
}